Speaker: Ahmad Khalil Ibrahimi, Radiation Oncologist, King Hussein Cancer Center
Ahmad Khalil Ibrahimi: Hello, this is Doctor Ahmad Khali Ibrahimi, a radiation oncologist from King Hussein Cancer Center, Amman Jordan. Stereotactic Radio Surgeon is one of the many standard treatments for patients with brain metastasis from solid tumors, particularly in those with good performance status and limited brain metastasis. We know however, that immunotherapy and targeted therapy have the ability to penetrate the blood brain barrier and induce a response on brain metastasis. The objective of our study was to try to find out how these agents impacted the outcomes of patients with brain metastasis, whether administered concomitantly or non-concomitantly with a stereotactic radio surgery. And to try to find out this interaction between these two treatment modalities. The main target audience are radiation oncologists, medical oncologists and the neurosurgeons. If you are interested in the results, please join us at the Annual Meeting of the American Society of Therapeutic Radiation Oncology. Hall C, September 30th, 10:45 a.m. till 12 p.m. Thank you.
